Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.75 |
| ▸ | MEN1 | O00255 | 4/20 | 0.75 |
| ▸ | TP53 | P04637 | 1/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.75 |
| ▸ | FAAH | O00519 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19049371 | 0.86 | KDM4E (0.70) | KDM4EKMT2AMEN1TP53MAPK1 | |
| SCHEMBL1600111 | 0.84 | KMT2A (0.65) | KDM4EKMT2AMEN1TP53MAPK1 | |
| SCHEMBL21169301 | 0.83 | KMT2A (0.73) | KDM4EKMT2AMEN1TP53MAPK1 | |
| SCHEMBL19002677 | 0.83 | KMT2A (0.66) | KDM4EKMT2AMEN1TP53MAPK1 | |
| SCHEMBL13149176 | 0.82 | PKM (0.68) | KDM4EKMT2AMEN1TP53MAPK1 | |
| Hydrochloric Acid SCHEMBL27433739 | 0.82 | KMT2A (0.65) | KDM4EKMT2AMEN1TP53MAPK1 | |
| SCHEMBL19002261 | 0.82 | POLB (0.73) | FAAHALDH1A1PKM | |
| SCHEMBL18182316 | 0.81 | MAPK1 (0.72) | KDM4EKMT2AMEN1TP53MAPK1 | |
| SCHEMBL5055449 | 0.81 | ALDH1A1 (0.74) | KDM4EKMT2AMEN1TP53MAPK1 | |
| SCHEMBL19002260 | 0.80 | ALDH1A1 (0.76) | KDM4EKMT2AMEN1FAAHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | KDM4E 3392/4885KMT2A 3544/4885MEN1 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.